BOSTON — Alloy Therapeutics has entered into a multi-year agreement with AbbVie to develop a next-generation antibody discovery platform aimed at targeting disease areas that remain difficult to address with current technologies.
Under the terms of the agreement, Alloy will receive an upfront payment along with additional compensation tied to the delivery of the platform. The collaboration will provide AbbVie with access to the new platform as part of its broader research and development efforts.
The partnership reflects Alloy’s strategy of building and deploying platform-based technologies to support drug discovery across the biotechnology sector. The company said the agreement reinforces its focus on enabling partners with tools designed to accelerate the development of antibody therapeutics.
Alloy’s ATX-Gx platform, which utilizes fully humanized transgenic mice, is already widely adopted across the industry, with more than 200 partners using the system to support therapeutic discovery programs. The company said it continues to reinvest in expanding its platform capabilities, including developing new strains and tools to meet evolving research needs.
“We believe the best technologies are built in close collaboration with partners who share our commitment to innovation and real-world impact,” said Davide Schiavone, senior director and head of genetically engineered organisms at Alloy Therapeutics. “This agreement with AbbVie allows us to design a platform that reflects what scientists truly need with practical, modular tools that streamline therapeutic discovery and expand what’s possible in antibody engineering.”
Alloy said the collaboration is expected to further strengthen its position in the antibody discovery space as demand grows for more precise and efficient approaches to drug development.
